Latest news with #CloverHealth
Yahoo
23-07-2025
- Business
- Yahoo
Clover Health (CLOV) Announced a New Pharmacy Pilot Program in New Jersey
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the . On July 9, Clover Health Investments, Corp. (NASDAQ:CLOV) announced a new pharmacy pilot program in New Jersey. The new program is being launched in partnership with IPC Digital Health, which connects independent community pharmacies across the state. The program is aimed at helping seniors. Management noted that local pharmacies in the iCare+ network will be the backbone of this initiative. As these pharmacies already know their communities and will use new technology and virtual services to assist patients, especially those with chronic health conditions. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. A key part of the program is using real-time tools, powered by Clover Health Investments, Corp. (NASDAQ:CLOV)'s data and AI. These tools will monitor if prescriptions are filled and help spot when patients miss doses. Pharmacists will work closely with doctors and care teams to ensure seniors always get the right medicine at the right time, close to where they live. Clover Health Investments, Corp. (NASDAQ:CLOV) is a technology company that helps improve healthcare for people on Medicare, especially seniors. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
21-07-2025
- Business
- Yahoo
Why Is Clover Health (CLOV) Stock Soaring Today
What Happened? Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 9.5% in the afternoon session after the stock gained ground amid broader positive market sentiment ahead of a busy week for corporate earnings. U.S. stock futures pointed to a higher open for the markets, creating a positive backdrop for investors who were anticipating a full slate of earnings reports from major companies during the week. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. In the absence of any fresh catalysts from the healthcare technology company, its shares appeared to be lifted by the general market updraft. Is now the time to buy Clover Health? Access our full analysis report here, it's free. What Is The Market Telling Us Clover Health's shares are extremely volatile and have had 44 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 10 days ago when the stock dropped 4.8% on the news that a filing revealed that the company's CEO, Wai Conrad, sold a portion of his holdings. According to a regulatory filing on July 11, 2025, CEO Wai Conrad sold 15,203 shares of Class A Common Stock on July 8 for a total of approximately $49,561. The transactions were made at prices ranging from $3.25 to $3.27 per share. While the sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows insiders to sell a predetermined number of shares at a predetermined time, the news can still create unease among investors. Insider selling, even when planned, is often scrutinized by the market for any signals about a company's future prospects, contributing to negative pressure on the stock price. Clover Health is up 1.4% since the beginning of the year, but at $3.18 per share, it is still trading 34.1% below its 52-week high of $4.82 from January 2025. Investors who bought $1,000 worth of Clover Health's shares 5 years ago would now be looking at an investment worth $285.27. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-07-2025
- Business
- Yahoo
Clover Health to Participate in Upcoming Canaccord Genuity 45th Annual Growth Conference
WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ('Clover,' 'Clover Health' or the 'Company'), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 11:00 a.m. Eastern Time. A live webcast and replay of the presentation will be accessible from Clover Health's investor relations website at About Clover Health:Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence and Congestive Heart Failure, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease. Investor Relations:Ryan Schmidtinvestors@ Press Inquiries:press@ in to access your portfolio
Yahoo
12-07-2025
- Business
- Yahoo
Why Clover Health (CLOV) Shares Are Trading Lower Today
Shares of health insurance company Clover Health (NASDAQ:CLOV) fell 4.8% in the afternoon session after a filing revealed that the company's CEO, Wai Conrad, sold a portion of his holdings. According to a regulatory filing on July 11, 2025, CEO Wai Conrad sold 15,203 shares of Class A Common Stock on July 8 for a total of approximately $49,561. The transactions were made at prices ranging from $3.25 to $3.27 per share. While the sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows insiders to sell a predetermined number of shares at a predetermined time, the news can still create unease among investors. Insider selling, even when planned, is often scrutinized by the market for any signals about a company's future prospects, contributing to negative pressure on the stock price. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Clover Health? Access our full analysis report here, it's free. Clover Health's shares are extremely volatile and have had 45 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Clover Health is down 7.2% since the beginning of the year, and at $2.91 per share, it is trading 39.7% below its 52-week high of $4.82 from January 2025. Investors who bought $1,000 worth of Clover Health's shares 5 years ago would now be looking at an investment worth $261.71. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-07-2025
- Business
- Yahoo
Craig-Hallum Reiterates a Buy Rating on Clover Health Investments (CLOV), Sets a $6 PT
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the 13 Stocks Under $5 With High Upside Potential. In a report released on May 7, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Clover Health Investments, Corp. (NASDAQ:CLOV) with a price target of $6.00. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company reported notable fiscal Q1 2025 results that support this optimistic outlook, with Medicare Advantage membership for the quarter reaching 103,418, representing a 30% year-over-year increase. Total revenue for fiscal Q1 2025 rose 33% year-over-year to $462 million, while adjusted EBITDA reached $26 million, reflecting a significant 279% year-over-year rise. Adjusted net income also grew 322% year-over-year to $25 million. In addition, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a GAAP net loss of $1 million, compared to $19 million a year ago, suggesting a considerable improvement in its operations. Clover Health Investments, Corp. (NASDAQ:CLOV) is a physician enablement technology company that offers Medicare Advantage plans in the United States. It offers PPO and HMO Medicare Advantage plans in several US states. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
